Combined Liver and Kidney Transplantation with Particular Reference to Positive Cytotoxic Crossmatches

Similar documents
HLA HISTOCOMPATIBILITY AND LIVER TRANSPLANT SURVIVAL

RESULTS previously reported from this center

SINCE the introduction of Imuran and

LIVER TRANSPLANTATION

LYMPHAPHERESIS IN ORGAN TRANSPLANTATIOH:

Definitions. You & Your New Transplant ` 38

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 November 29.

Reprinted from TRANSPLANTATION AND CLINICAL IMMUNOLOGY VOLUME XIII Proceedings of the Thirteenth International Course, Lyon, June 15-17, 1981

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.

Total Hepatectomy and Liver Replacement (Orthotopic Liver Transplantation) for Primary Hepatic Malignancy

This article demarcated the end of the experimental phase of. clinical liver transplantation from the beginning of the

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

PEDIATRIC LIVER TRANSPLANTATION

1. Discuss the basic pathophysiology of end-stage liver and kidney failure.

Liver Transplantation for Biliary Atresia. D.H. Van Thiel, M.D., J.S. Gavaler, B.S., 2 2 B.J. Zitelli, M.D., J.J. Malatack, M.D.

Glossary. Anesthesiologist A doctor who puts you or parts of your body to sleep during surgery.

TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard

Clinical Questions of Combined Liver Kidney Transplantation

Immunosuppression and Other Nonsurgical Factors in the Improved Results of Liver Transplantation

Experience in 1,000 Liver Transplants Under Cyclosporine-Steroid Therapy: A Survival Report

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 July 14.

Hepatic artery thrombosis following pediatric liver transplantation: Assessment of blood flow measuremen,t in allografts

Kidney Transplantation

Transplantation. Immunology Unit College of Medicine King Saud University

Ron Shapiro, MD, Abdul S. Rao, MD, D. Phil., Paulo Fontes, MD, Adrianna Zeevi, Ph.D., Mark Jordan, MD, Velma P. Scantlebury, MD,

Dictionary of Organ Donation and Transplantation Terms

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

LIVER AND KIDNEY TRANSPLANTATION IN CHILDREN RECEIVING CYCLOSPORIN A AND STEROIDS

NAPRTCS Annual Transplant Report

ORIGINAL ARTICLE. Received April 30, 2007; accepted June

UEMS & EBS: DIVISION OF TRANSPLANT SURGERY

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant

- Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ.

Pediatric Kidney Transplantation

Renal Transplant. Tony Chacon. Program Head BCIT Nephrology Nursing Program.

Liver Transplant Immunosuppression

WITH the use of Cy A for clinical liver transplantation,

HETEROAGGLUTININS AND THEIR SIGNIFICANCE IN BABOON HEPATIC XENOTRANSPLANTATION

The Incidence, Timing, and Management of Biliary Tract Complications After Orthotopic Liver Transplantation

NAPRTCS Annual Transplant Report

Paired Donation. Andrew Bradley Rachel Johnson Joanne Allen Susan V Fuggle. Cambridge University NHS Hospitals NHS Foundation trust

Effect of Race Upon Organ Donation and Recipient Survival in Liver Transplantation

Vol. 29, pp.585 ~ 589, ml. 1.6 mg/dl 1 MRSA. Table 1 MRI

Cyclosporin A and steroids for liver and heart transplantation

Hepatectomy in Children

BILIARY TRACT COMPLICATIONS IN HUMAN ORTHOTOPIC LIVER TRANSPLANTATION 1,2

Current Status of Hepatic Transplantation

MISDIAGNOSED MALIGNANCY IN TRANSPLANTED ORGANS.

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency

Induction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation

Renal Transplantation at the University of Pittsburgh: The Impact of FK506

University of Groningen. Blood platelets in liver transplantation Pereboom, Ilona Tapke Annie

SURGERY, TRANSPLANTATION AND POLYCYSTIC DISEASE. Mr Nick Inston PhD FRCS Consultant Transplant Surgeon Queen Elizabeth Hospital Birmingham

NAPRTCS Annual Report

Extrahepatic Biliary

NAPRTCS Annual Report

ABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function

TDM. Measurement techniques used to determine cyclosporine level include:

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 December 3.

Targeted Adverse Event (ADV)

Immunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency

PEDIATRIC RENAL TRANSPLANTATION - INDIAN EXPERIENCE

NONSPECIFIC Starts in the blood by

NIH Public Access Author Manuscript Res Commun Chem Pathol Pharmacol. Author manuscript; available in PMC 2010 October 18.

Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts

The Acceptable Mismatch program of Eurotransplant.

Hong Kong Journal Nephrol of 2000;(2): Nephrology 2000;2(2): BR HAWKINS ORIGINAL A R T I C L E A point score system for allocating cadaver

Long term liver transplant management

Blood Component Testing and Labeling

NIH Public Access Author Manuscript Surg Clin North Am. Author manuscript; available in PMC 2011 April 29.

30- liver Transplantation for Inborn Errors of Metabolism*

CLINICAL PRESENTATION OF HEPATIC ARTERY THROMBOSIS AFTER LIVER TRANSPLANTATION IN THE CYCLOSPORINE ERA1,2

Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos

KIDNEY TRANSPLANT ATION

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

Should red cells be matched for transfusions to patients listed for renal transplantation?

SCI.RWDSING GLOXERULONEPHRITIS (FSGN) OF CHILDHOOD. Jerry XcCauley, X.D. Andreas G. Tzakis, X.D. John J. Fung, X.D., Ph.D. satoru Todo, M.D.

Blood Group Incompatible Renal Transplantation and Apheresis. Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT

Liver Transplantation

Renal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

M. Ho, C. P. Wajszczuk, A. Hardy, J. S. Dummer, T. E. Starzl, T. R. Hakala, and H. T. Bahnson OUR study involves 216 patients transplanted

Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab

Patient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant

NAPRTCS Annual Report

IMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar

ORIGINAL ARTICLE. Simultaneous Liver-Kidney Transplantation for Adult Recipients With Irreversible End-Stage Renal Disease

Chapter 22: Hematological Complications

PUO in the Immunocompromised Host: CMV and beyond

Organ transplantation in Bulgaria

Over the past 6 decades, solid organ transplantation

The New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health

Bacteraemia in patients receiving human cadaveric

Desensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver

Case Presentation Turki Al-Hussain, MD

Transcription:

T.E. Starzl. A. Tzakis. L. Makowka. J. Fung. G. Klintmalm. S. Todo. R. Gordon. and M. Griffin 40 Combined Liver and Kidney Transplantation with Particular Reference to Positive Cytotoxic Crossmatches SUMMARY Nine patients were provided with 10 livers and 10 kidneys. Nine of the paired allografts were from the same donors. Seven of the 9 recipients are alive after 6 to 26 months. At least 3 and possibly as many as 5 of the paired transplantations were to patients whose sera possessed preformed antigraft cytotoxic antibodies. Only one of the livers seemed harmed by the antibodies, and the kidneys that were transplanted after the livers were in place were thereby seemingly protected from antibody injury in 2 of the 3 unequivocal cases. These observations may provide a clue for the development of new methods to prevent hyperacute renal rejection. INTRODUCTION In a recent inquiry by an Italian journalist, the question was posed, "Do you think that in the next decade a 'puzzle man' with heart, liver, and pancreas taken from other human beings might be feasible?" The answer is that there are already examples of puzzle men who have received a heart and kidney, a pancreas and kidney, a heart and lungs, and even a heart and liver taken from other human beings. The increasing boldness with which transplantation is being developed makes it certain that other and more com- From the Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania plicated combinations will be forthcoming in the near future. The extent to which multiple organ transplantation has entered our clinical consciousness could be illustrated by any of the foregoing multiple organ procedures, particularly by hundreds of cases of combined renal and pancreas transplantation. However, in this communication we will describe the less well known combination of hepatic and renal transplantation from common or different donors. The subject holds a special fascination, since the liver apparently can protect a subsequently transplanted kidney from the hyperacute rejection that is caused by recipient anti-donor cytotoxic antibodies. METHODS Nine patients aged 12 to 65 years with a variety of hepatic and renal diseases were studied. One patient had a liver plus kidney transplant on two occasions. In each case but one, the primary reason for proceeding was end-stage liver disease in which the expectation of survival was limited to a few weeks or months (Table 1). In the exceptional patient, the diagnosis was polycystic liver and renal disease. Hepatic function in this patient was normal, but she was dying of respiratory insufficiency caused by expansion of her enormously enlarged liver, which at the time of its removal weighed 13 kg (28.6 pounds) (Fig. 1). The serum creatinine level in this exceptional patient was 2.1 mg%, but her creatinine clearance was estimated at 20 to 25 ml/minute. 24

N U1 r- <' ~ III ::l Q. Table 1. Clinical Factors in 9 Patients who had Liver and Kidney Transplants,.. OT Preop < Num- Date of Liver Date Kidney Liver Kidney Preop Cr CCr Cause of -t iil ber Age/Sex Transplant Transplant Disease Disease (mg%) (ml/min) Outcome Death ::l 419 44/F 7/22/84 Same Polycystic Polycystic 2 20-25 Alive III ::l... 464 15/F 11/18/84 Same Polycystic with Polycystic and On 0 Alive cirrhosis glomerulo- Dialysis :E g: nephritis 495 43/F 2/12/85 Same Primary biliary Glomerulo- 4 20 Alive 0 ";:0: cirrhosis nephritis <' 164 39/F 6/16/85 Same Rejection of Indeterminate 6 10 Died Fungal CD previous 7/7/85 infection (") 0 graft after 6 years 3 a 6/28/85 Same Dearterialized n ~ graft CD 584 dialysis 38/M 8/15/85 Same Postnecrotic Glomerulo- 4 10 Alive cirrhosis nephritis 680 50/M 12/19/85 3/25/86 Postnecrotic Did not recover On 0 Alive cirrhosis from Dialysis hepatorenal syndrome 708 34/M 1/28/86 Same Micronodular Glomerulo- 2.1 30 Alive cirrhosis nephritis 725 65/M 2/22/86 Same Alcoholic Glomerulo- 2.5 Not done Died Pneumocystis cirrhosis nephritis 6/28/86 pneumonia 736 12/M 3/4/86 Same Cysteamine Cystinosis 6 5 Alive toxicity but on c: ::l CD ~ Abbreviations: OT = orthotopic transplant; Cr. = Creatinine; CCr = CCr = creatinine clearance.

26 Starzl, et al. a few hours, the kidneys from the same donors were inserted. Immunosuppressive therapy consisted of cyclosporine (CsA) and prednisone, to which monoclonal antibody therapy (OKT3) was added early in the postoperative period in 2 patients. The Iymphocytotoxic crossmatches were perfomled with conventional techniques as described in detail elsewhere. I In the patients who possessed preformed cytotoxic antibodies against their donors, the reactivity and specificity of the antibodies were assessed with absorption techniques. I The amount of blood lost in the various cases is listed in Table 2. The blood loss data was considered important because of the possibility of dilution of the recipient antibodies by transfusion. RESULTS Mortality Fig. 1. Thirteen Kg polycystic liver replaced in patient OT 464. The other 8 patients had various degrees of renal insufficiency, ranging from total renal failure (cases OT 464 and OT 680) to early renal failure, which under ordinary circumstances would not have called for immediate treatment by either renal transplantation or diajysis (Table 1). Eight of the 9 patients had transplantations of both organs from a common donor. The ninth patient (OT 680) had a liver replacement on December 19, 1985. When the preexisting renal failure showed no sign of recovery 3 months later, an immediately functioning renaj transplant was placed from another donor. Tissue matching was random in all cases, and the tissue matches at the A, B, and Dr loci were poor (Table 2). In 3 of the 10 transplants that were performed in 9 patients, there were unequivocally cytotoxic crossmatches of the kind which, under ordinary circumstances, would have precluded renal transplantation (Table 2). In these 3 instances and in 2 other patients with doubtfully crossmatches, the liver grafts were placed first, and after One of the 9 recipients died 25 days after an initial double organ transplantation and 10 days after a second similar attempt. This recipient had been treated with liver transplantation in 1979 (6 years previously) using azathioprine-steroid maintenance therapy. The liver had slowly failed over a period of many months during which efforts at salvage were made by the late institution of CsA. Renal failure which was already present was made worse. The first attempt at retransplantation on June 16, 1985 failed because of thrombosis of the hepatic artery with secondary failure of the concomitantly placed kidney. The defective liver was removed at another operation on June 28, 1985, leaving in place the kidney graft which had not functioned. Although both the liver and kidney placed on June 28 functioned, the patient died of fungemia 10 days later. Patient OT 725, a 65 year old man, died of Pneumocystis carinii pneumonitis 4 months after hepatic and renal transplantation. He had been treated with heavy immunosuppression because of persistent and recurrent rejection of both organs. Graft Function The other 7 patients are well from 6 to 26 months postoperatively. All 7 have essentially normal hepatic function and 6 have web-functioning renal grafts. [n those patients whose pre-existing renal failure was not yet poor enough to justify transplantation on such grounds alone, radionuclide scans have shown that the renal allograft has become the dominant organ (Fig. 2).

Liver and Kidney Transplants with Positive Crossmatches 27 Table 2. Typing and Serologic Data. at Donor- HLA Panel Num- Recipient Antigens Reactive ber ABO Matched Antibody 419 B-8 A29 0% 464 B-8 0% 495 A-A 0 94% 164a 0-0 0 0% 164b AI, B8 0% 584 B-8 A2 0% 680 0-0 Liver AI, 0% DR3 Kidney 0 708 A-A A2 0% 725 0-0 0 21% 736 0-0 A2 91% Preop Blood Cytotoxic Loss Crossmatch Crossmatch Crossmatch (ml) After LTX Later Negative 2400 Doubtful 8000 Strongly 3000 Negative Negative Negative 2400 Negative Negative 1600 Negative Negative 2400 Negative Negative Negative Doubtful 6000 Strongly 8000 Doubtful Strongly 20,000 Strongly One patient with cystinosis, whose liver had been destroyed by an idiosyncratic reaction to experimental therapy with cysteamine, went through a very stonny and protracted postoperative course but eventually attained completely nonnal hepatic function. Although the renal graft from the same donor has blood flow, it has not yet functioned satisfactorily after 6 months. The Influence of Preformed Antigraft Antibodies Hyperacute rejection of the 3 hepatic grafts that were confronted with cytotoxic antidonor antibodies did not occur. However, one of the recipients experienced massive fibrinolysis, which necessitated intensive phannacologic and surgical care in an operation that lasted nearly 24 hours. It was suspected that the liver had undergone an abortive attack by antibodies. Although 50 units of blood were required in this small 12-year-old child, the crossmatch with the donor remained. Two of the renal grafts that were put in place after the liver had been revascularized functioned promptly and permanently. The cytotoxic antibodies in these 2 recipients were reduced or had disappeared after the liver was in place (Table 2). However, the kidney placed in patient OT 736 against a persistent cytotoxic crossmatch did not function at the time and has not functioned properly in the subsequent 6 months. Although the renal allograft had fair blood flow on a radionuclide scan, it undoubtedly sustained a severe and possibly irreversible insult from the antibody attack. DISCUSSION Patients being considered for liver transplantation have presented to us with a high incidence of secondary renal failure from the hepatorenal syndrome, drug toxicity, shock, and other causes. 2.3 Renal transplantation in conjunction with hepatic replacement under such circumstances is not usually a serious consideration, since provision of good liver function usually corrects the renal pathophysiology; complete recovery of the kidneys is expected. Imaging techniques such as ultrasound or CT scan are invaluable in assessing potential reversibility. If the kidneys are small and shrunken, the diagnosis of significant chronic renal disease can be considered established. If chronic renal disease is documented, concomitant renal transplantation may be indicated. Combined hepatic and renal transplantation is apt to become more common in the years ahead. Chronic renal disease is often seen in patients with end-stage liver disease, especially in those in whom the diagnosis is chronic active hepatitis, a disease that is frequently associated with glomerulonephritis. Other examples

28 Starzl, et al. B Fig. 2. Radionuclide can in patient OT 495. Note the dominance of the transplant compared with the di eased native kidneys. The upper scan demonstrates flow to the transplant kidney. the lower, secretion. The transplant was in the right iliac fossa. in our serie were patients with polycystic disease of both liver and kidney. In such liver recipients, it would be futile to attempt hepatic transplantation without providing a kidney as well.. ill 7 of our 9 patients, renal transplantation was carried out at a stage of chronic renal disease that ordinarily would not have been considered appropriate for renal transplantation. There were two reasons for proceeding early. First, it was impossible to envision going forward with liver transplantation using the nephrotoxic immuno uppressive drug esa, without ensuring good renal fu nction. Otherwise, the optimal immunosuppression for the liver would have been jeopardized. Second, the sera of a significant number of patients contained T-warm cytotoxic antibodies of the kind which preclude renal tran plantation in the event of anti-donor specificity. In the event of a crossmatch, it was expected that the liver would provide protection for the kidney from the same donor. thus providing a unique and one time

Liver and Kidney Transplants with Positive Crossmatches 29 only opportunity for patients whose cytotoxic antibodies were widely reactive. The basis for the speculation was the well known resistance of the liver to hyperacute rejection caused by such antibodies. 4-6 This hypothesis was supported not only by the clinical observations reported here but also by special serologic tests. In patients OT 495 and 725, strongly crossmatches before the liver was revascularized becan1e negative or doubtfully in the subsequent hours, allowing the kidneys to be transplanted in an antibody depleted milieu. The specificity with which the antibodies were deleted was well demonstrated in patient OT 495, whose sera retained widely reactive antibodies at the same time as the antibodies against the donor lymphocytes were lost. This case and others have been reported in detail elsewhere. It is noteworthy that good kidney function was not obtained in a third patient whose antibodies did not disappear after transplantation of the liver. Although there was good evidence of immunologic advantage endowed by the liver upon the kidney in the foregoing examples, the long-term effect of multiple organ transplantation on the outcome of individual organs is not known. Although evidence can be cited from numerous publications that multiple organs protect each other, 7 an almost equal number of citations to the contrary could be found by the reader with the converse bias. For the moment, we have concluded that neither a clear advantage nor disadvantage is demonstrable with multiple organs. REFERENCES 1. Fung JJ, Griffin M, Duquesnoy RJ. Shaw BW Jr, and Starzl TE: Successful sequential liver-kidney transplantation in a patient with preformed lymphocytotoxic antibodies Transplant Proc 19: 767-768, 1987 2. Iwatsuki S, Popovtzer M, Corman J, Ishikawa M, Putnam CW, Katz FH, and Starzl TE: Recovery from "hepatorenal syndrome" after orthotopic liver transplantation N Eng J Med 289: 1155, 1973 3. Ellis D, Avner ED, and Starzl TE: Renal failure in children with hepatic failure undergoing liver transplantation J Pediatr 111: 393. 1986 4. Starzl TE, Koep LJ, Halgrimson CG, Hood J, Schroter GPJ, Porter KA, and Weil R III: Fifteen years of clinicalliver transplantation Gastroenterol 77: 375, 1979 5. Iwatsuki S, Iwaki Y, Kano T, Klintmalm G. Koep LJ, Wei I R III, and Starzl TE: Successful liver transplantation from crossmatch donors Transplant Proc 13: 286, 1981 6. Gordon RD, Fung JJ, Markus B, Fox I, Iwatsuki S, Esquivel CO, Tzakis A, Todo S, and Starzl TE: The antibody crossmatch in liver transplantation Surgery 100: 705-715,1986 7. Starzl TE: Experience in hepatic transplantation Philadelphia: Saunders, 1969, p 187